HomeBlogPsychedelics

Ontario tweaks Business Corporations Act, making it more business-friendly

This summer, two small but important amendments to the Business Corporations Act (Ontario) came into effect. These amendments eased restrictions on governance so that Ontario businesses can operate more efficiently, ensuring consistency with other Canadian jurisdictions.   Effective July 5, 2021, the new amendments also reduced approval thresholds for written shareholder resolutions and led to ...

Psychedelics treatments are in the public eye  

Recently the use of psychedelics in health care experienced an interesting turning point – not through political gains, but through television.      Hulu’s latest hit, Nine Perfect Strangers, depicts the use of psychedelics as a tool in mental health therapy. Now, for anyone who’s seen the show – which follows a wellness retreat gone wrong – it’s ...

Micro-dosing with Zeifmans: Season 2 podcast recap

Season 2 of our podcast “Micro-dosing with Zeifmans” was a real trip. Pulling knowledge from industry expert guests, we examined the industry as it currently is, and painted a vivid picture of the future as well. Some of the topics we covered include: – Current state of regulatory challenges – Driving force for future ...

Will stock option taxation changes hurt hiring?

Employers in Canada’s emerging industries like cannabis, psychedelics, and agritech are concerned about how upcoming changes to the taxation of stock options will impact their ability to recruit top talent. Traditionally, stock options are among the most enticing incentives used to attract senior talent; particularly the type of executives who are equipped to drive ...

For psilocybin, the hits keep coming

As we’ve spoken about in previous blog posts, the psychedelics industry has been rapidly expanding to become a key component in the treatment of a host of mental illnesses. With multiple parties progressing promising research studies, industry players going public, and regulations across the world relaxing for the industry, the future is looking brighter ...

Summary of our psychedelics podcast series: “Micro-dosing with Zeifmans”

Innovations in psychedelics are poised to disrupt the pharmaceutical industry, and the Zeifmans Cannabis and Psychedelics Team has been hard at work in the space and is here to demystify these interesting developments. We’re proud to announce our entry into podcasting, having recently launched a brand-new endeavor: “Micro-dosing with Zeifmans”. To listen, look us ...

Psychedelics investors are seeking 3 key qualities

Research is proving the impressive efficacy of psychedelics in treating conditions like anxiety, depression, and opioid addiction. Psychedelic substances like MDMA, LSD, ketamine, and most notably psilocybin (magic mushrooms) have been gaining traction in recent years as several clinical trials enter Phase II and beyond. And as the cannabis industry has experienced some undeniable ...